Sanibel Captiva Trust Company Inc. Takes $532,000 Position in Cencora, Inc. (NYSE:COR)

Sanibel Captiva Trust Company Inc. bought a new position in Cencora, Inc. (NYSE:COR - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 1,913 shares of the company's stock, valued at approximately $532,000.

Several other institutional investors have also recently made changes to their positions in COR. JFS Wealth Advisors LLC increased its stake in Cencora by 63.0% in the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock worth $27,000 after buying an additional 46 shares during the period. Banque Transatlantique SA purchased a new position in Cencora in the 4th quarter worth about $29,000. SBI Securities Co. Ltd. purchased a new position in Cencora in the 4th quarter worth about $30,000. Kentucky Trust Co purchased a new position in Cencora in the 4th quarter worth about $33,000. Finally, WASHINGTON TRUST Co increased its stake in Cencora by 37.7% in the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock worth $38,000 after buying an additional 46 shares during the period. Institutional investors own 97.52% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Wells Fargo & Company raised shares of Cencora from an "equal weight" rating to an "overweight" rating and raised their price target for the stock from $274.00 to $337.00 in a research note on Tuesday, June 3rd. Citigroup raised their target price on shares of Cencora from $330.00 to $355.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. Morgan Stanley set a $288.00 target price on shares of Cencora in a research report on Tuesday, April 15th. UBS Group raised their target price on shares of Cencora from $298.00 to $335.00 and gave the company a "buy" rating in a research report on Tuesday, April 29th. Finally, Wall Street Zen raised shares of Cencora from a "hold" rating to a "buy" rating in a research report on Wednesday, March 12th. One equities research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $306.91.

Cencora Stock Up 0.0%

Shares of Cencora stock traded up $0.08 on Friday, reaching $295.12. The stock had a trading volume of 966,888 shares, compared to its average volume of 1,528,880. The company has a 50 day moving average price of $287.24 and a 200 day moving average price of $261.82. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. Cencora, Inc. has a 1 year low of $218.65 and a 1 year high of $309.35. The stock has a market capitalization of $57.20 billion, a P/E ratio of 41.98, a P/E/G ratio of 1.31 and a beta of 0.58.

Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.07 by $0.35. The firm had revenue of $75.50 billion for the quarter, compared to the consensus estimate of $75.41 billion. Cencora had a net margin of 0.46% and a return on equity of 328.62%. The company's quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.80 EPS. As a group, equities research analysts forecast that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, June 2nd. Shareholders of record on Friday, May 16th were given a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 0.75%. The ex-dividend date was Friday, May 16th. Cencora's dividend payout ratio is presently 25.52%.

Insiders Place Their Bets

In other Cencora news, CEO Robert P. Mauch sold 4,969 shares of Cencora stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $289.33, for a total transaction of $1,437,680.77. Following the completion of the sale, the chief executive officer now directly owns 47,582 shares in the company, valued at approximately $13,766,900.06. The trade was a 9.46% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Chairman Steven H. Collis sold 14,579 shares of the company's stock in a transaction on Tuesday, April 22nd. The shares were sold at an average price of $281.81, for a total transaction of $4,108,507.99. Following the completion of the sale, the chairman now directly owns 315,913 shares in the company, valued at $89,027,442.53. This trade represents a 4.41% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 38,253 shares of company stock valued at $10,582,297. Insiders own 10.80% of the company's stock.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.